Sanghwa Ko1, Hongjae Jo1, Seongpil Yun1, Eunyoung Park1, Suk Kim1, Hyung-Il Seo1. 1. Sanghwa Ko, Hongjae Jo, Seongpil Yun, Eunyoung Park, Hyung-Il Seo, Department of Surgery, Biomedical Research Institute, Pusan National University Hospital, Busan 602-739, South Korea.
Abstract
AIM: To evaluate the therapeutic efficacy of radiofrequency ablation (RFA) for resectable colorectal liver metastases (CRLM) compared with that of resection. METHODS: Between June 2004 and June 2009, we retrospectively analyzed 29 patients with resectable CRLMs; 17 patients underwent RFA, and 12 underwent hepatic resection. All of the patients were informed about the treatment modalities and were allowed to choose either of them. RFA including an intraoperative approach was performed by a radiologist; otherwise, hepatic resection was performed by a surgeon. Comparative analysis of the two groups was performed, including comparisons of gender, age, and clinical outcomes, such as primary tumor stage and survival rates. RESULTS: The mean tumor size was significantly larger in the resection group (3.59 cm vs 2.02 cm, P < 0.01), and the 5-year overall survival (OS) rate for all patients was 44.7%. There was no difference in the 5-year OS rates between the RFA and resection groups (37.8% vs 66.7%). Univariate analysis indicated significantly lower 5-year OS rates for patients with a tumor size > 3 cm. The 5-year disease-free survival (DFS) rates were 17.6% and 22.2% in the RFA and resection groups, respectively (P = 0.119). Univariate analysis revealed that in cases of male gender, age > 65 years, T stage < IV, absence of lymphatic metastasis, and tumor size > 3 cm, RFA resulted in significantly inferior 5-year DFS rates compared with surgical resection. CONCLUSION: Surgical resection revealed superior outcomes in the treatment of resectable CRLMs, particularly in cases with a hepatic tumor size > 3 cm.
AIM: To evaluate the therapeutic efficacy of radiofrequency ablation (RFA) for resectable colorectal liver metastases (CRLM) compared with that of resection. METHODS: Between June 2004 and June 2009, we retrospectively analyzed 29 patients with resectable CRLMs; 17 patients underwent RFA, and 12 underwent hepatic resection. All of the patients were informed about the treatment modalities and were allowed to choose either of them. RFA including an intraoperative approach was performed by a radiologist; otherwise, hepatic resection was performed by a surgeon. Comparative analysis of the two groups was performed, including comparisons of gender, age, and clinical outcomes, such as primary tumor stage and survival rates. RESULTS: The mean tumor size was significantly larger in the resection group (3.59 cm vs 2.02 cm, P < 0.01), and the 5-year overall survival (OS) rate for all patients was 44.7%. There was no difference in the 5-year OS rates between the RFA and resection groups (37.8% vs 66.7%). Univariate analysis indicated significantly lower 5-year OS rates for patients with a tumor size > 3 cm. The 5-year disease-free survival (DFS) rates were 17.6% and 22.2% in the RFA and resection groups, respectively (P = 0.119). Univariate analysis revealed that in cases of male gender, age > 65 years, T stage < IV, absence of lymphatic metastasis, and tumor size > 3 cm, RFA resulted in significantly inferior 5-year DFS rates compared with surgical resection. CONCLUSION: Surgical resection revealed superior outcomes in the treatment of resectable CRLMs, particularly in cases with a hepatic tumor size > 3 cm.
Authors: S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: Hyuk Hur; Yong Taek Ko; Byung Soh Min; Kyung Sik Kim; Jin Sub Choi; Seung Kook Sohn; Chang Hwan Cho; Heung Kyu Ko; Jong Tai Lee; Nam Kyu Kim Journal: Am J Surg Date: 2008-09-11 Impact factor: 2.565
Authors: Nathaniel P Reuter; Charles E Woodall; Charles R Scoggins; Kelly M McMasters; Robert C G Martin Journal: J Gastrointest Surg Date: 2008-10-30 Impact factor: 3.452
Authors: Brian Davidson; Kurinchi Gurusamy; Neil Corrigan; Julie Croft; Sharon Ruddock; Alison Pullan; Julia Brown; Maureen Twiddy; Jaqueline Birtwistle; Stephen Morris; Nick Woodward; Steve Bandula; Daniel Hochhauser; Raj Prasad; Steven Olde Damink; Marielle Coolson; K van Laarhoven; Johannes Hw de Wilt Journal: Health Technol Assess Date: 2020-04 Impact factor: 4.014
Authors: Kurinchi Gurusamy; Neil Corrigan; Julie Croft; Maureen Twiddy; Stephen Morris; Nick Woodward; Steve Bandula; Daniel Hochhauser; Vicky Napp; Alison Pullan; Nicholas Jakowiw; Raj Prasad; Steven Olde Damink; C J H M van Laarhoven; Johannes H W de Wilt; Julia Brown; Brian R Davidson Journal: Trials Date: 2018-02-13 Impact factor: 2.279
Authors: Byoung Chul Lee; Hyun Gu Lee; In Ja Park; So Yeon Kim; Ki-Hun Kim; Jae Hoon Lee; Chan Wook Kim; Jong Lyul Lee; Yong Sik Yoon; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889